BE853086A - Compositions pharmaceutiques contenant comme ingredients actifs des derives de triazolo-pyrimidines utiles pour le traitement de psoriasis - Google Patents

Compositions pharmaceutiques contenant comme ingredients actifs des derives de triazolo-pyrimidines utiles pour le traitement de psoriasis

Info

Publication number
BE853086A
BE853086A BE176289A BE176289A BE853086A BE 853086 A BE853086 A BE 853086A BE 176289 A BE176289 A BE 176289A BE 176289 A BE176289 A BE 176289A BE 853086 A BE853086 A BE 853086A
Authority
BE
Belgium
Prior art keywords
triazolo
psoriasis
treatment
pharmaceutical compositions
active ingredients
Prior art date
Application number
BE176289A
Other languages
English (en)
Inventor
A K Ganguly
E A Peets
A K Saksena
Original Assignee
Scherico Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherico Ltd filed Critical Scherico Ltd
Publication of BE853086A publication Critical patent/BE853086A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE176289A 1976-04-05 1977-03-31 Compositions pharmaceutiques contenant comme ingredients actifs des derives de triazolo-pyrimidines utiles pour le traitement de psoriasis BE853086A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67378576A 1976-04-05 1976-04-05

Publications (1)

Publication Number Publication Date
BE853086A true BE853086A (fr) 1977-09-30

Family

ID=24704115

Family Applications (2)

Application Number Title Priority Date Filing Date
BE176288A BE853085A (fr) 1976-04-05 1977-03-31 Nouvelles triazolo-pyrimidines
BE176289A BE853086A (fr) 1976-04-05 1977-03-31 Compositions pharmaceutiques contenant comme ingredients actifs des derives de triazolo-pyrimidines utiles pour le traitement de psoriasis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BE176288A BE853085A (fr) 1976-04-05 1977-03-31 Nouvelles triazolo-pyrimidines

Country Status (10)

Country Link
US (1) US4076711A (fr)
JP (2) JPS52122632A (fr)
AU (2) AU2384177A (fr)
BE (2) BE853085A (fr)
DE (2) DE2714254A1 (fr)
DK (2) DK146077A (fr)
FR (2) FR2347367A1 (fr)
NL (2) NL7703515A (fr)
SE (2) SE7703787L (fr)
ZA (2) ZA771998B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2918261A1 (de) * 1978-05-09 1979-11-15 Bristol Myers Co Neue purinderivate, verfahren zu deren herstellung, sie enthaltende arzneimittel und zwischenprodukte
US5204353A (en) * 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
LU86547A1 (fr) * 1986-08-07 1988-03-02 Oreal Suspension pour induire et stimuler la croissance des cheveux et diminuer leur chute a base de derives de la pyrimidine
ES2051886T3 (es) * 1987-04-07 1994-07-01 Ciba Geigy Ag Procedimiento para la obtencion de nuevos derivados de la 3h-1,2,3-triazolo(4,5-d)pirimidina.
US4916224A (en) * 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
US4950758A (en) * 1988-01-20 1990-08-21 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US4931559A (en) * 1988-01-20 1990-06-05 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5631370A (en) * 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5175292A (en) * 1988-01-20 1992-12-29 Regents Of The University Of Minnesota Intermediates for the preparation of dideoxycarbocyclic nucleosides
US4996116A (en) * 1989-12-21 1991-02-26 General Electric Company Enhanced direct bond structure
US5514688A (en) * 1990-09-14 1996-05-07 Merrell Dow Pharmaceuticals Inc. Carbocyclic adenosine analogs useful as immunosuppressants
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
CA2051012C (fr) * 1990-09-14 2002-04-02 David R. Borcherding Analogues carbocycliques de l'adenosine pouvant etre utilises comme immunosuppresseurs
US5817661A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
AU658698B2 (en) * 1991-12-06 1995-04-27 Aventis Pharmaceuticals Inc. Novel trans cyclopentanyl purine analogs useful as immunosuppressants
US5817672A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5723466A (en) * 1991-12-06 1998-03-03 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5817660A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
NZ331647A (en) * 1996-03-26 2000-03-27 Du Pont Pharm Co Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
ZA971896B (en) 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
ZA972497B (en) 1996-03-27 1998-09-25 Du Pont Merck Pharma Arylamino fused pyridines and pyrimidines
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (fr) 1997-05-30 2002-08-20 Cell Pathways, Inc. Methode d'identification de composes visant a inhiber les lesions neoplasiques, compositions pharmaceutiques a prtir de ces composes et compositions pour traiter les lesions neoplasiques
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
DE19838705A1 (de) 1998-08-26 2000-03-02 Bayer Ag Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
EP1703668A1 (fr) * 2005-03-18 2006-09-20 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Système pour traiter des paramètres "qualité de service" (qos) dans un réseau de communications
CN101438288A (zh) * 2006-03-15 2009-05-20 Csir公司 谷氨酰胺合成酶的磷酰基转移酶活性的调节
GB2451594A (en) * 2006-03-15 2009-02-04 Csir Modulation of phosphoryl transferase activity of glutamine synthetase
US8148385B2 (en) 2006-10-31 2012-04-03 Janssen Pharmaceutica N.V. Substituted [1,2,3] triazolo[4,5-d]pyrimidine derivatives as ADP P2Y12 receptor antagonists
WO2008054795A2 (fr) * 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Dérivés de triazolopyrimidine convenant comme antagonistes du récepteur p2y12 de l'adp
JP4927502B2 (ja) * 2006-11-08 2012-05-09 東京電力株式会社 ケーブル拘束装置
UA111640C2 (uk) * 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
EP3505171A4 (fr) 2016-08-26 2020-08-26 Mitsubishi Tanabe Pharma Corporation Composé hétérocyclique azoté bicyclique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407204A (en) * 1944-07-22 1946-09-03 American Cyanamid Co Triazolo (d) pyrimidines and methods of preparing the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2918261A1 (de) * 1978-05-09 1979-11-15 Bristol Myers Co Neue purinderivate, verfahren zu deren herstellung, sie enthaltende arzneimittel und zwischenprodukte
US5204353A (en) * 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith

Also Published As

Publication number Publication date
BE853085A (fr) 1977-09-30
US4076711A (en) 1978-02-28
SE7703786L (sv) 1977-10-06
DK146677A (da) 1977-10-06
DE2714263A1 (de) 1977-10-13
AU2384277A (en) 1978-10-05
NL7703515A (nl) 1977-10-07
SE7703787L (sv) 1977-10-06
DE2714254A1 (de) 1977-10-06
JPS52122632A (en) 1977-10-15
JPS52122395A (en) 1977-10-14
FR2347367A1 (fr) 1977-11-04
NL7703514A (nl) 1977-10-07
ZA771998B (en) 1978-03-29
FR2347044A1 (fr) 1977-11-04
DK146077A (da) 1977-10-06
AU2384177A (en) 1978-10-12
ZA771997B (en) 1978-03-29

Similar Documents

Publication Publication Date Title
BE853086A (fr) Compositions pharmaceutiques contenant comme ingredients actifs des derives de triazolo-pyrimidines utiles pour le traitement de psoriasis
BE854414A (fr) Compositions pharmaceutiques pour le traitement de l'hypertrophie benigne de la prostate
FR2342072A1 (fr) Composition enzymatique pour le traitement de la cataracte
FR2338271A1 (fr) Derives du phtalane, procede pour leur preparation, et compositions pharmaceutiques contenant de tels derives
BE859817A (fr) Compositions notamment utiles pour le traitement de l'acne
OA05577A (fr) Procédé de préparation de compositions pharmaceutiques renfermant des pyréthrinoïdes.
JPS55108860A (en) Hydroxypropylltriazole*its manufacture and use as medicine
NO144455C (no) Fremgangsmaate ved fremstilling av terapeutisk aktive nye piperidinderivater.
BE865156A (fr) Compositions pharmaceutiques pour le traitement des depressions
BE837662A (fr) Composition gelifiee contenant de la tretinoine pour le traitement de l'acne
IT8019711A0 (it) Composizioni da usarsi come cosmetici e procedimento per lapreparazione dei loro ingredienti attivi.
ES425514A1 (es) Un procedimiento para la preparacion de nuevas 3-nitrocuma-rinas.
ES432848A2 (es) Procedimiento para la obtencion de derivados de alcanolami- na.
BE885291A (fr) Compositions pharmaceutiques pour le traitement des dysfonctionnements cardiaques
BE854137A (fr) Composition pharmaceutiques de traitement de l'acne
ATE14982T1 (de) Zusammensetzungen mit gehalt an paromomycin zur oertlichen behandlung der leishmaniasis der haut.
BE872908A (fr) Compositions pharmaceutiques pour le traitement de l'hypertension
NL7601629A (nl) Werkwijze ter bereiding van werkzame verbindingen ten gebruike in parfumcomposities, alsmede voor het bereiden van parfumposities en geparfumeerde voortbrengselen.
BE860162A (fr) Derives actifs de l'uree leur procede de preparation ainsi que les compositions therapeutiques les contenant
BE809832A (fr) Compositions pharmaceutiques pour le traitement de maladies de la peau
BE820222A (fr) Composition therapeutique pour le traitement du diabete par voie orale
PT65151B (fr) Procede pour la preparation de nouvelles solutions pharmaceutiques stables
FR2334362A1 (fr) Composition pharmaceutique pour le traitement de l'hyperuricemie
BE812974A (fr) Compositions pharmaceutiques pour le traitement des ulceres
BE829024A (fr) Compositions pharmaceutiques pour le traitement de l'hydropisie